 This research study is studying a new type of vaccine as a possible treatment for patients with MGMT-unmethylated glioblastoma. This research study is a Phase I clinical trial, which tests the safety of an investigational intervention and also tries to define the appropriate dose of the intervention to use for further studies. Investigational means that the intervention is being studied and that research doctors are trying to find more about it. It also means that the FDA U.S. Food and Drug Administration has not approved the Personalized NeoAntigen Cancer Vaccine for any use in patients, including people with glioblastoma. 